Repligen Corp
RGEN
查看詳細走勢圖
157.390USD
-4.270-2.64%
收盤 12/12, 16:00（美東）報價延遲15分鐘
8.86B總市值
5641.22本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-2.64%
5天
-4.60%
1月
-0.39%
6月
+19.87%
今年開始到現在
+9.34%
1年
+0.90%
查看詳細走勢圖
TradingKey Repligen Corp股票評分
單位: USD 更新時間: 2025-12-12操作建議
Repligen Corp當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在醫療設備與耗材行業排名19/208位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價187.96。中期看，股價處於上升通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Repligen Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
22
分析師
買入
評級
187.959
目標均價
+16.88%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Repligen Corp亮點
亮點風險
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
業績轉虧
公司業績轉虧，最新年度虧損美元
估值高估
公司最新PE估值5641.22，處於3年歷史高位
機構減倉
最新機構持股55.23M股，環比減少10.18%
加拿大豐業銀行分紅基金持倉
明星投資者加拿大豐業銀行分紅基金持倉，最新持倉40.66K股
Repligen Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Repligen Corp簡介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代碼RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
網址https://www.repligen.com/
常見問題
Repligen Corp(RGEN)的當前股價是多少？
Repligen Corp(RGEN)的當前股價是 157.390。
Repligen Corp 的股票代碼是什麼？
Repligen Corp的股票代碼是RGEN。
Repligen Corp股票的52週最高點是多少？
Repligen Corp股票的52週最高點是182.520。
Repligen Corp股票的52週最低點是多少？
Repligen Corp股票的52週最低點是102.965。
Repligen Corp的市值是多少？
Repligen Corp的市值是8.86B。
Repligen Corp的淨利潤是多少？
Repligen Corp的淨利潤為-25.51M。
現在Repligen Corp(RGEN)的股票是買入、持有還是賣出？
根據分析師評級，Repligen Corp(RGEN)的總體評級為買入，目標價格為187.959。
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是多少
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是0.028。
相關品種
+1.52%
+1.77%
-1.14%
-0.92%
-2.60%
+0.90%
+0.32%
+0.12%
+0.50%
-1.74%
-0.32%
+0.90%
+0.44%
+0.23%
-0.47%
-1.38%
-2.23%
+0.05%
-2.43%
-0.05%
